I'd be surprised if there haven't been offers to license MPL. The initial fee would fund the study but the milestone payments are only realised after approval. Therefore licensing offers a low risk opportunity for BP to participate in a potential blockbuster. If MPL gains FDA approval the greater returns to shareholders will always be gained by avoiding licensing deals and selling the whole thing. I would prefer to wait and see this thing through. It will be worth billions if successful.
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman, page-59
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14100 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 35400 | 2 |
View Market Depth
| Last trade - 11.48am 20/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable